Evidence map›Paper›PMID 36371312›Full record

ArticleJournal of cystic fibrosis : official journal of the European Cystic Fibrosis Society2023

Contemporary cystic fibrosis incidence rates in Canada and the United States.

Anne L Stephenson, Sana Swaleh, Jenna Sykes, Sanja Stanojevic, Xiayi Ma, Bradley S Quon, Albert Faro, Bruce Marshall, Kathleen J Ramos, Josh Ostrenga and 4 more

Abstract read
In one paragraph

Article in Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Primary ciliary dyskinesia.Paediatrics & child health · 2025
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Cystic fibrosis.Nature reviews. Disease primers · 2024
    Review
  11. Cystic fibrosis prevalence in the United States and participation in the Cystic Fibrosis Foundation Patient Registry in 2020.Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Anne L StephensonSt. Michael's Hospital, Department of Respirology, University of Toronto, Toronto, ON, Canada; Keenan Research Centre, Li Ka Shing Knowledge Institute, Toronto, ON, Canada; Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada. Electronic address: anne.stephenson@unityhealth.to.
Sana SwalehSt. Michael's Hospital, Department of Respirology, University of Toronto, Toronto, ON, Canada.
Jenna SykesSt. Michael's Hospital, Department of Respirology, University of Toronto, Toronto, ON, Canada.
Sanja StanojevicDepartment of Community Health and Epidemiology, Dalhousie University, Halifax, Nova Scotia.
Xiayi MaSt. Michael's Hospital, Department of Respirology, University of Toronto, Toronto, ON, Canada.
Bradley S QuonSchool of Population and Public Health, University of British Columbia, Vancouver, BC, Canada; Centre for Heart Lung Innovation, University of British Columbia and St. Paul's Hospital, Division of Respiratory Medicine, Department of Medicine, University of British Columbia, Vancouver, BC, Canada.
Albert FaroCystic Fibrosis Foundation, 4550 Montgomery Ave, Suite 1100N, Bethesda, Maryland, United States 20814.
Bruce MarshallCystic Fibrosis Foundation, 4550 Montgomery Ave, Suite 1100N, Bethesda, Maryland, United States 20814.
Kathleen J RamosDivision of Pulmonary, Critical Care, and Sleep Medicine Department of Medicine and Pediatrics, University of Washington Medical Center, Seattle, Washington, United States.
Josh OstrengaCystic Fibrosis Foundation, 4550 Montgomery Ave, Suite 1100N, Bethesda, Maryland, United States 20814.
Alex ElbertCystic Fibrosis Foundation, 4550 Montgomery Ave, Suite 1100N, Bethesda, Maryland, United States 20814.
Sameer DesaiCentre for Heart Lung Innovation, University of British Columbia and St. Paul's Hospital, Division of Respiratory Medicine, Department of Medicine, University of British Columbia, Vancouver, BC, Canada.
Elizabeth CromwellCystic Fibrosis Foundation, 4550 Montgomery Ave, Suite 1100N, Bethesda, Maryland, United States 20814.
Christopher H GossDivision of Pulmonary, Critical Care, and Sleep Medicine Department of Medicine and Pediatrics, University of Washington Medical Center, Seattle, Washington, United States; Division of Pulmonary and Sleep Medicine, Department of Pediatrics, University of Washington, Seattle, Washington, United States.

Funding

Translational Research Center to Expedite Novel Therapies in Cystic FibrosisP30DK089507 · NIDDK · SEATTLE CHILDREN'S HOSPITAL · PI Christopher Hooper Goss · 2010 to 2026
$21.4M
Early Intervention in Pulmonary Exacerbation in CFR01HL103965 · NHLBI · UNIVERSITY OF WASHINGTON · PI GOSS, CHRISTOPHER HOOPER, LECHTZIN, NOAH · 2010 to 2014
$3.8M
Investigating treatment resistance mechanisms in chronic bacterial infectionsR01AI101307 · NIAID · UNIVERSITY OF WASHINGTON · PI BRUCE, JAMES EDWARD, MANOIL, COLIN · 2012 to 2016
$2.9M
Regulation of host inflammatory responses and outcome in melioidosis by TLR5R01HL113382 · NHLBI · UNIVERSITY OF WASHINGTON · PI WEST, TIMOTHY EOIN · 2012 to 2016
$2.6M
Predicting survival and planning for lung transplantation in severe cystic fibrosisK23HL138154 · NHLBI · UNIVERSITY OF WASHINGTON · PI RAMOS, KATHLEEN JESSICA · 2017 to 2021
$947k
FDA HHS R01 FD003704NHLBI NIH HHS K23 HL138154NHLBI NIH HHS R01 HL103965NHLBI NIH HHS R01 HL113382NIAID NIH HHS R01 AI101307NIDDK NIH HHS P30 DK089507
6 · The paper itself

Abstract

backgroundThe availability of new diagnostic algorithms for cystic fibrosis (CF), changing population demographics and programs that impact family planning decisions can influence incidence rates. Thus, previously reported incidence rates in Canada and the United States (US) may be outdated. The objectives of this study were to estimate contemporary CF incidence rates in Canada and the US and to determine if the incidence rate has changed over time.

methodThis population-based cohort study utilized data between 1995-2019 from the Canadian CF Registry (CCFR), Statistics Canada, US CF Foundation Patient Registry (CFFPR) data, and US Center for Disease Control (CDC) National Vital Statistics System. Incidence was estimated using the number of live CF births by year, sex, and geographic region using Poisson regression, with the number of live births used as the denominator. To account for delayed diagnoses, we imputed the proportion of diagnoses expected given historical trends, and varying rates of newborn screening (NBS) implementation by region.

resultsAfter accounting for implementation of NBS and delayed diagnoses, the estimated incidence rate for CF in 2019 was 1:3848 (95% CI: 1:3574, 1:4143) live births in Canada compared to 1:5130 (95% CI:1:4996, 1:5267) in the US. There was substantial regional variation in incidence rates within both Canada and the US. Since 1995, incidence rates have decreased at a rate of 1.6% per year in both countries (p<0.001).

conclusionContemporary CF incidence rates suggest CF incidence is lower than previously reported and varies widely within North America. This information is important for resource planning and for tracking how programs (e.g., genetic counselling, modulator availability etc.) may impact the incidence of CF moving forward.

Indexed as

Cystic FibrosisCanadaCohort StudiesHumansIncidenceInfant, NewbornNeonatal ScreeningUnited StatesCystic fibrosisIncidenceInternational comparisonRegional differences

Identifiers

PMID36371312
PMCPMC11214606

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.